FDA-cleared maintenance regimen incorporates palbociclib with trastuzumab ± pertuzumab and endocrine therapy after 4–8 induction cycles without progression in HR ...

Approval establishes sacituzumab govitecan as a first-line option across PD-L1 strata, including monotherapy when checkpoint inhibitors are unsuitable and combination therapy for PD-L1 CPS ≥10 tumors.

In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to ...

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...

They want to make sure we've got more control over that supply chain, so DARPA and the federal government are really ...

Examining the drivers of 340B drug program growth, the impact of vertical integration and contract pharmacies, the ongoing legal and regulatory disputes, and the strategic considerations life sciences ...

Clinical Affairs plays a central role in ensuring that CGM promotional claims are accurate, evidence-based, and compliant. By ...

Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...

An FDA pilot targeting early clinical development seeks to shorten IND-to–first-patient timelines by six to 12 months, potentially shifting capital allocation, IRR models, and milestone-driven ...

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...

Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...

In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timelines by six to 12 months as the US looks to reclaim ...